{
    "2021-03-16": [
        [
            {
                "time": "2023-10-15",
                "original_text": "Eli Lilly's Mirikizumab Beat Placebo At Controlling, Resolving Ulcerative Colitis Symptoms",
                "features": {
                    "keywords": [
                        "Mirikizumab",
                        "placebo",
                        "ulcerative colitis",
                        "symptoms"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-16",
                "original_text": "Lilly (LLY) Down as Alzheimer's Drug Fails Investor Expectation",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Alzheimer's",
                        "drug",
                        "fails",
                        "investor expectation"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-17",
                "original_text": "Dip in Eli Lilly Stock Makes It a Buy, Mizuho Analyst Says",
                "features": {
                    "keywords": [
                        "dip",
                        "Eli Lilly",
                        "stock",
                        "buy",
                        "Mizuho analyst"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "The Zacks Analyst Blog Highlights: MGM Resorts, American Airlines, Blackstone Group, Extended Stay America and Eli Lilly",
                "features": {
                    "keywords": [
                        "Zacks",
                        "analyst blog",
                        "MGM Resorts",
                        "American Airlines",
                        "Blackstone Group",
                        "Extended Stay America",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals",
                        "travel",
                        "real estate"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-19",
                "original_text": "AstraZeneca to supply U.S. with extra 500,000 doses of COVID-19 antibody-based cocktail",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "U.S.",
                        "COVID-19",
                        "antibody-based cocktail",
                        "doses"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-20",
                "original_text": "UPDATE 1-Eli Lilly bowel disease treatment succeeds in late-stage study",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "bowel disease",
                        "treatment",
                        "late-stage study"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-21",
                "original_text": "Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study",
                "features": {
                    "keywords": [
                        "Mirikizumab",
                        "clinical remission",
                        "ulcerative colitis",
                        "Phase 3 induction study"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}